DoH Policies screened during the period: 1st July 2018 – 30th September 2018

In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).

Documents

Equality Impact Assessment - Amendments to Article 77 of the Mental Health (Northern Ireland) Order 1986 – EQIA
PDF (114 KB)

NICE Technology Appraisal TA521 - Guselkumab for treating moderate to severe plaque psoriasis
PDF (67 KB)

NICE Technology Appraisal TA523 - Midostaurin for untreated acute myeloid leukaemia
PDF (110 KB)

NICE Technology Appraisal TA524 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (review of TA446)
PDF (109 KB)

NICE Technology Appraisal TA525 - Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
PDF (109 KB)

NICE Technology Appraisal TA526 - Arsenic trioxide for treating acute promyelocytic leukaemia
PDF (117 KB)

NICE Technology Appraisal TA527 - Beta interferons and glatiramer acetate for treating multiple sclerosis (review of TA32)
PDF (118 KB)

NICE Technology Appraisal TA530 - Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
PDF (104 KB)

NICE Technology Appraisal TA531 - Pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer (review of TA447)
PDF (112 KB)

NICE Technology Appraisal TA532 - Cenegermin for treating neurotrophic keratitis
PDF (102 KB)

NICE Technology Appraisal TA533 - Ocrelizumab for treating relapsing–remitting multiple sclerosis
PDF (107 KB)

NICE Technology Appraisal TA534 - Dupilumab for treating moderate to severe atopic dermatitis
PDF (66 KB)

NICE Technology Appraisal TA535 - Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
PDF (114 KB)

NICE Technology Appraisal TA536 - Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
PDF (109 KB)

NICE Technology Appraisal TA537 - Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
PDF (128 KB)

NICE Technology Appraisal TA538 - Dinutuximab beta for treating neuroblastoma
PDF (108 KB)

NICE Public Health Guideline NG90 - Physical activity and the environment
PDF (72 KB)

NICE Public Health Guideline NG92 - Stop smoking interventions and services
PDF (140 KB)

Consultation on regulations to restrict smoking in private vehicles carrying children
PDF (117 KB)

Prohibiting the sale of nicotine inhaling products (NIPs), including e-cigarettes, to persons under the age of eighteen
PDF (149 KB)

Health and Social Care Workforce Strategy
PDF (122 KB)

Proposals to review Fees and Bursary Support for Individuals Training to become HSC Professionals
PDF (189 KB)

Help viewing documents